--- title: "2026 Symposium" description: "The Vascular Access Society of the Americas (VASA) is a multidisciplinary organization dedicated to enhancing dialysis access care through education, research, and advocacy. Join VASA for expert-led events, access the Journal of Vascular Access, and connect with professionals committed to advancing" url: "https://vasamd.org/events/symposium/symposium-agenda" date: "2026-06-13T05:03:48+00:00" language: "en-GB" --- # 2026 Symposium ![](https://vasamd.org/_resources/images/symposium/2026/banner.webp)The Vascular Access Society of the Americas invites you to participate as an exhibitor at the 2026 Vascular Access for Dialysis Symposium, May 20-22, 2026 at the Hilton Salt Lake City Center in Salt Lake City, Utah. This Symposium is designed for all transplant, vascular and general surgeons, nephrologists, interventional radiologists and nephrologists, nurses and allied health professionals who are interested in the management of vascular access. The VASA Symposium is an excellent opportunity for your company to showcase its products and services to a multidisciplinary audience committed to advancing dialysis patient care. The Program Committee is busy planning an excellent scientific meeting that will include: - State-of-the-art lectures covering all major areas in dialysis access - Diverse multi-disciplinary faculty including prominent international - speakers representing Europe, Asia, Canada, South America, & Japan - 40 scientific abstract presentations - Vascular access nursing and allied health - New devices and technologies - Video presentations ## Thank You 2026 Symposium Sponsors [ ![Gore](https://vasamd.org/_resources/images/symposium/2026/gore.webp) ](https://www.goremedical.com/)Platinum Sponsor [ ![Merit Medical](https://vasamd.org/_resources/images/symposium/2026/meritmedical.webp) ](https://www.merit.com/)Platinum Sponsor [ ![BD](https://vasamd.org/_resources/images/symposium/2026/bd.webp) ](https://www.bd.com/en-us)Gold Sponsor [ ![Laminate Medical Technologies](https://vasamd.org/_resources/images/symposium/2026/laminate.webp) ](https://www.laminatemedical.com/)Gold Sponsor [ ![Venova](https://vasamd.org/_resources/images/symposium/2026/venova.webp) ](https://venovamedical.com/)Silver Sponsor [ ![Xeltis](https://vasamd.org/_resources/images/symposium/2026/xeltis.webp) ](https://xeltis.com/)Silver Sponsor Thank you for attending the 2026 VASA Symposium in Salt Lake City! We hope it was not only an great educational experience for you, but an opportunity to reconnect with your peers! Flickr is an inclusive global community of photography enthusiasts and the best place for inspiration, connection, and sharing! Follow VASA on Flickr! [ Photo Gallery ](https://www.flickr.com/photos/195822710@N04/albums/72177720333589827) ​ Please use the login information you were previously provided to access the presentations from the 2026 VASA Symposium. [Please contact VASA Headquarters](mailto:info@vasamd.org) with any questions. Remember Me - [Forgot your password?](https://vasamd.org/component/users/reset) - [Forgot your username?](https://vasamd.org/component/users/remind) | WEDNESDAY, MAY 20, 2026 — ALLIED HEALTH PROGRAM | |---| | **07:00 AM - 07:30 AM** | Breakfast | | **07:30 AM - 07:35 AM** | Welcome Speaker: Debbie Brouwer-Maier, RN, CNN | | **07:35 AM - 07:50 AM** | [ ESKD Life Plan and Access Plan](#wed0735am) The 2019 KDOQI Vascular Access Guidelines are based on an individualized modality plan and dialysis access plan to support the PD or HD for patients in the later stages of CKD. The dialysis access process of care is based on the Life Plan and supporting Dialysis Access Plan. The KDOQI guideline interpretation and implementation are based on the individual patient's ESKD Life-Plan and Dialysis Access Plan. **Learning Objectives** - Discuss the progress to create and update a patient's ESKD Life-Plan and Dialysis Access Plan. - Discuss the KDOQI Guidelines impetration and implementation are based on the patient's ESKD Life-Plan and Dialysis Access Plan. Speaker: Debbie Brouwer-Maier, RN, CNN | | **07:50 AM - 08:20 AM** | [ AV Access Creation, HD Catheter and PD Placement](#wed0750am) Basics of AVF and AVG creation, HD catheter placement and PD catheter placement. **Learning Objectives** - Learn how the different access techniques are performed. - Learn the problems related to each access modality. Speaker: John Lucas, MD | | **08:20 AM - 09:05 AM** | Patient Models at Stations: 1-min Check with Patients, Physical Exams Speakers: John Lucas, MD; Dirk Hentschel, MD; Jacquelyn N. Hall, CCHT, VAC | | **09:05 AM - 09:20 AM** | Break | | **09:20 AM - 09:50 AM** | [ VASA Toolkit for Show & Tell](#wed0920am) Dialysis Access Devices for Nurses **Learning Objectives** - Understand tunneled catheter design and function. - Understand graft for cannulation. Speakers: John Lucas, MD; Dirk Hentschel, MD; | | **09:50 AM - 10:20 AM** | [ Cannulation Stations](#wed0950am) Hands-on stations for demostration of various cannulation techniques with time for the partipants to do a return demonstration. **Learning Objectives** - Demonstration of the proper cannulation methods using a hands-on model. - Discussion of the proper Rope Ladder or Buttonhole cannulation techniques. Speakers: Debbie Brouwer-Maier, RN, CNN; Amber Parker; Crystal Fahner | | **10:20 AM - 11:15 AM** | [ ANNA Intermountain Chapter Collaboration Session: 360 degree Care of the Nephrology Patient](#wed1020am) The three speakers will share the presentation, focusing on the journey of a CKD patient as they approach starting dialysis and on the role of the nephrology nurse/care team. They will include issues like anemia and other complications of CKD that impact the process of care for the Life Plan and Dialysis Access Plan. They may use a case presentation or a collection of case presentations. **Learning Objectives** - Outline the distinct roles of nursing professionals in the care of persons requiring kidney care. - Using case studies with audience participation, review the interventions used to initiate and maintain kidney care. Speakers: Kristin Larson, AGNP-BC, CNN, FANNA; Kennadi Lower, RN, BSN; Melanie Kreitzer, BSN, RN, CNN | | **11:15 AM - 11:30 AM** | Break | | WEDNESDAY, MAY 20, 2026 — PLENARY & GENERAL SESSIONS | |---| | **11:30 AM - 12:00 PM** | [ The Holland Keynote Lecture: Best Cannulation Practices are Achievable](#wed1130am) Compare current US cannulation to advancements achived outside the US, such as POCUS for cannulation mapping and real-time cannulation, different needle gauges and designs, standardized cannulation guidelines, and training. Call to action to improve the US standard of care by adopting more advanced cannulation techniques. **Learning Objectives** - Discuss the current state of cannulation in the US. - Discuss advancements commonly used outside the US including means to implement change in the US clinical practice. Speaker: Debbie Brouwer-Maier, RN, CNN | | **CANNULATION** | | **12:00 PM - 12:10 PM** | [ Needle Designs and Impact on Cannulation](#wed1205pm) Expand on the various needle designs currently available in the US. Review the design elements that impact the vascular access and how improved designs can help to decrease known issues with the commonly US utilized metal needle design. **Learning Objectives** - Discuss the design elements of the various needles and the clinical impact of the design elements. Speaker: Debbie Brouwer-Maier, RN, CNN | | **12:11 PM - 12:19 PM** | [ Eradicating Area Cannulation / Dead Space Between Dialysis Needles](#wed1211pm) Emphasizing the importance of early site rotation. Show the detrimental effects of area cannulation. **Learning Objectives** - Learn to start rope and ladder cannulation early on. - Learn to periodically look for additional sites for cannulation. Speaker: John Lucas, MD | | **12:20 PM - 12:28 PM** | Covered Stent Grafts in Cannulation Segment Speaker: Alexander Ushinsky, MD | | **12:29 PM - 12:35 PM** | Q&A Panel Discussion Panelists: Debbie Brouwer-Maier, RN, CNN; John Lucas, MD; Alexander Ushinsky, MD | | **12:35 PM - 01:35 PM** | Lunch Symposium - Dialysis Access Decisions: Where Data, Guidelines, and Patient Needs Align Speakers: Stephen Hohmann, MD; Yana Etkin, MD Sponsored by: Gore & Associates | | **USRDS** | | **01:35 PM - 01:45 PM** | 2025 USRDS: A Fundamental Failure of Systems of Access Placement in the US Speaker: Victoria Teodorescu, MD, MBA, RVT | | **01:46 PM - 01:56 PM** | [ Progress and Paradox: What the 2025 USRDS Report Reveals About Vascular Access](#wed0146pm) The 2025 USRDS report reveals a paradox in dialysis access care: improved outcomes once access is established, yet persistently high catheter use at initiation. Declines in abandonment and infection rates highlight advances in access management, but failures in predialysis planning remain widespread. This presentation examines this disconnect and its implications for enhancing future access strategy. **Learning Objectives** - Evaluate contemporary trends in vascular access outcomes from the USRDS 2025 report, including improvements in access durability and infection rates among prevalent hemodialysis patients. - Apply risk-based, multidisciplinary strategies to reduce catheter dependence at dialysis initiation. Speaker: Robert Lee, MD | | **01:57 PM - 02:07 PM** | How can we get Nephrologists to Refer Patients for Access Earlier? Speaker: Jose Navarrete, MD | | **02:08 PM - 02:18 PM** | [ Artificial Intelligence will Save the Day (or Not)](#wed0208pm) Artificial Intelligence (AI) is increasingly influencing vascular access care, with applications spanning device selection, insertion, and complication prevention. Advanced analytics and real-time decision support offer the potential to improve appropriateness of device utilization, enhance vessel preservation—particularly in patients with kidney disease—and reduce complications such as thrombosis and infection, while reinforcing adherence to evidence-based practices and value-based care frameworks. Despite this promise, adoption remains constrained by limitations in data quality, workflow fragmentation, interoperability challenges, and concerns related to bias and transparency, with many solutions lacking rigorous prospective validation. Absent robust governance structures and meaningful clinician engagement, implementation may be suboptimal, underscoring the necessity for AI to augment—rather than replace—clinical judgment. This session will provide a balanced and pragmatic assessment of AI in vascular access, emphasizing current applications, inherent limitations, and strategies for responsible, scalable integration into clinical practice. Speaker: Karthik Ramani, MD | | **02:19 PM - 02:29 PM** | [ ESRD Networks: Is CMS oversight effective?](#wed0219pm) Provide a brief overview of the history of the quality measures related to vascular access in the ESRD Quality Incentive Program (QIP). Review the current vascular access quality measure to include overall dialysis facility performance and payment penalties enforced by CMS. Conclude with the patient and provider critiques of this aspect of the ESRD QIP. **Learning Objectives** - At the conclusion of this session, participants will understand the current quality measure included in the ESRD QIP covering vascular access. - At the conclusion of this session, participants will understand what is missing from the current ESRD QIP related to vascular access. Speaker: Andrew D. Howard, MD, FACP | | **02:30 PM - 02:40 PM** | Q&A Panel Discussion Panelists: Victoria Teodorescu, MD, MBA, RVT; Robert Lee, MD; Jose Navarrete, MD; Karthik Ramani, MD; Andrew D. Howard, MD, FACP | | **02:50 PM - 03:20 PM** | Break | | **ACCESS PARADIGMS** | | **03:21 PM - 03:31 PM** | [ Not a One-and-Done: Role of Surgeons in Longitudinal Access Surveillance and Maintenance](#wed0321pm) My message will be that continued longitudinal followup of our patients after access creation and maturation is critical to avoid complications and ensure happy patients and referral sources. **Learning Objectives** - Participants will be able to identify the four critical goals to be addressed at each visit. - Participants will be able to apply several techniques to use if complications arise. Speaker: Karl Illig, MD | | **03:32 PM - 03:42 PM** | [ What Does it Take to Improve Dialysis Access Outcomes?](#wed0332pm) Dialysis access outcomes fall short of many other procedural types. Reasons for this will be discussed and potential remedies will be offered. Speaker: Monnie Wasse, MD | | **03:43 PM - 03:53 PM** | Shared Decision Making - How? Speaker: Karen Woo, MD | | **03:54 PM - 04:00 PM** | Q&A Panel Discussion Panelists: Karl Illig, MD; Monnie Wasse, MD; Karen Woo, MD | | **04:01 PM - 04:21 PM** | DEBATE: OBL Vascular Access Centers vs Hospitals: The Good and the Bad Moderators: Stephen Hohmann, MD; John Ross, MD | | **04:22 PM - 04:52 PM** | [ Keynote Lecture - Toward an Unlimited Organ Supply: Translating Xenotransplantation to the Clinic](#wed0422pm) This session will review the scope and clinical consequences of organ shortage in kidney transplantation. The scientific rationale, recent clinical progress, and ongoing challenges of xenotransplantation as a potential solution to donor organ scarcity will be discussed. Participants will learn that the use of genetically engineered porcine organs for transplantation represents a scientifically advancing strategy to reduce waitlist mortality and address the persistent shortage of transplantable organs Speaker: Ragnar Palsson, MD | | **INNOVATION/BEST ABSTRACTS SESSION 1** | | **04:53 PM - 05:03 PM** | [ Early Fistula Maturation and Cannulation Outcomes of the VASQ U.S. Post-Market Randomized Controlled Study at an Ambulatory Surgery Center](#wed0453pm) **Introduction:** The clinical benefit of a permanently implanted nitinol scaffold to provide extravascular support for fistulas is being evaluated in the U.S. via a post-market, multicenter, randomized controlled trial. Here, initial outcomes from a single participating center will be presented. **Methods:** The study plans to enroll 300 extravascular supported (ES-AVFs) and unsupported (Control) fistulas, randomized 1:1, and compare the primary endpoint of time to cannulation success (confirmed via three-fourths successful two-needle cannulation over 30-day period). Additional data will be analyzed for 5-week cannulation readiness (referral for cannulation by the surgeon), primary failure (abandoned prior to maturation), interventions and patency over a 1-year follow-up period. All radiocephalic (RCF) and brachiocephalic (BCF) patients that consent will be included over multiple centers provided a superficial is not anticipated, without known central venous stenosis and 80 years old or younger. **Results:** This single site has enrolled 28 patients (13 ES-AVF and 15 Control) with sufficient follow-up data to assess maturation in 26 patients (12 ES-AVF and 14 Control). ES-AVF patients include 8 BCF and 5 RCF, and Control patients include 9 BCF and 6 RCF with similar demographics and comorbidities. Unassisted maturation was higher for ES-AVF patients at 41.7% vs 21.4% for control (Figure 1). Higher unassisted maturation rates correlated with higher 5-week cannulation readiness for ES-AVF patients at 33.3% vs 21.4% for Control patients. Similar primary failure rates were observed for ES-AVF at 25.0% vs 21.4% for controls. Fewer ES-AVF patients have required procedures to support maturation at 33.3% vs 64.3% for Control patients (Figure 1). The difference was largely driven by fewer angioplasties to assist maturation for ES-AVF patients who have required 0.08 per-patient vs 0.43 per-patient for controls (Figure 2). No angioplasties were performed due to stenosis for ES-AVF patients vs 70.0% of control patient angioplasties were to treat a clinically significant stenosis. ES-AVF offered fewer cannulation challenges with dialysis centers reporting “Difficult to Cannulate” for ES-AVF patients at a rate of 0.25 events per-patient vs 0.57 events per patient for controls. Additionally, ES-AVF patients reported no infiltrations to date vs 0.35 infiltrations per-patient for controls (Figure 2). **Conclusion:** The initial experience at this participating center in the VASQ U.S. Post-Market Randomized-Controlled confirms the early clinical benefits of ES-AVF to improve maturation rates with fewer interventions. ES-AVF appears to have a lower risk of early stenosis requiring angioplasty to mature fistulas as well as complications due to cannulation. Continued enrollment into the study will help elucidate any statistical differences between the two groups as the sample size grows. Speaker: Dion Franga, MD | | **05:04 PM - 05:11 PM** | [ Preserving Arteriovenous Access Circuits: 12-Month Results in Real-World Patients Following Kinetic Endovascular Micro-Incision Creation Prior to Plain Balloon Angioplasty for Treatment of Arteriovenous Access Dysfunction](#wed0504pm) The 12-month results from the FLEX FIRST AV Registry is a prospective, multi-center, real-world study evaluating the FLEX Vessel Prep™ System in patients with dysfunctional hemodialysis access. The study enrolled 130 patients across four U.S. centers, representing a diverse, high-risk population reflective of real-world clinical practice. The results demonstrated a compelling combination of safety, durability, and performance across complex lesion type by utilizing FLEX Vessel Prep and Kinetic Endovascular Micro-incision Creation (KEMIC) technology as a differentiated mechanical vessel preparation strategy. **Learning Objectives** - At the conclusion of this session, participants will be able to evaluate current standard of care algorithms for arteriovenous fistula maintenance and consider incorporating vessel prep with KEMIC ahead of destination therapies to optimize outcomes. - Participants will be able to apply real-world evidence to improve AV Access fistula durability. Speaker: Ari Kramer, MD | | **05:12 PM - 05:19 PM** | [ Initial Clinical Results of the Distal Staging Fistula in Catheter Dependent ESRD Patients](#wed0512pm) AVF is the ideal vascular access for hemodialysis. However, many patients are not eligible for a fistula, The Distal device is used to create an endovascular radial-radial arterio-venous fistula (AVF) at the wrist. Increased flow and pressure from the Distal device fistula are transmitted through perforator veins into the cephalic vein. The cephalic vein responds with dilation, wall remodeling, and progressive enlargement. A secondary surgical AVF utilizing the enlarged cephalic vein is then performed. Conclusions: In summary, most subjects have experienced benefits or are on track for benefiting from the Distal procedure. These patients did not have adequate veins for surgical fistula creation prior to the Distal procedure; they did not lose a potential access site as a result of the Distal procedure; and they did not experience AEs associated with the Distal device or procedure. Speakers: Michael Tal, MD, MBA; Ari Kramer, MD | | **05:20 PM - 05:27 PM** | [ Initial Feasibility Study of SelfWrap-Assisted Arteriovenous Fistulas (SW-AVF) - A 54-Month Report](#wed0520pm) Study results at 54 months. **Learning Objectives** - Appreciate outcomes with and without juxta-anastomotic wrap. Speaker: Dirk Hentschel, MD | | **05:28 PM - 05:35 PM** | [ The VENOS-2 Early Feasibility Study: One Year Outcomes of the Velocity® Percutaneous Arteriovenous Fistula ](#wed0528pm) Hemodialysis initiation with an AVF and minimizing CVC contact time remain critical unmet needs for patients with ESRD. Commercially available percutaneous AVF (pAVF) devices have demonstrated safe and reliable access creation; however, their adoption has been limited by high reintervention rates, need for flow-diversion procedures to achieve target vein maturation, and requirement for specialized cannulation training, all factors that collectively prolong catheter dependence. These limitations are largely attributable to a distributed venous outflow pattern that dissipates flow across the deep venous system, reducing flow in the superficial cannulation zone where maturation is needed. The Velocity pAVF System (Venova Medical, Los Gatos, CA) is an implant-based device designed to replicate surgical AVF anatomy by directing arterial flow exclusively into the superficial venous system, while simultaneously shielding the juxta-anastomotic endothelium from turbulence, a principal driver of anastomotic stenosis. Speaker: Robert Shahverdyan, MD, PhD | | **05:35 PM - 07:00 PM** | Reception & Poster Sessions | | THURSDAY, MAY 21, 2026 | |---| | **07:00 AM - 08:00 AM** | [ Breakfast Symposium - Consistency from Creation through Cannulation with VasQ Extravascular Support](#thu0700am) Can stabilizing hemodynamic and mechanical variables of fistula failure help standardize AVFs from creation through cannulation? And what does that mean for the definition of AVF success? These are the questions providers across the vascular access care continuum wrestle with every day. If these questions resonate with you, don’t miss Beyond the OR: Consistency from Creation through Cannulation with speakers Dr. Robert Shahverdyan and Dr. Monnie Wasse. Speakers: Robert Shahverdyan, MD, PhD; Monnie Wasse, MD Sponsored by: Laminate Medical Technologies | | **08:00 AM - 08:05 AM** | Opening Remarks Speaker: Charles Kim, MD | | **08:05 AM - 08:25 AM** | VASA Presidential Address Speaker: John Lucas, MD | | **AUTOGENOUS AV FISTULAS** | | **08:26 AM - 08:36 AM** | [ Vein Mapping: Ultrasound vs Venography](#thu0826am) The presentation will outline the key features of two techniques—ultrasound and venography—used to evaluate a patient’s vessels prior to vascular access creation. It will compare the advantages and limitations of each method and propose a recommended best-practice assessment pathway. **Learning Objectives** - At the conclusion of this session, participants will be able to understand the difference between two different techniques for vein mapping before arteriovenous fistula creation and will be able to select the most appropriate one based on patient specific factos. Speaker: Adina Voiculescu, MD | | **08:37 AM - 08:47 AM** | Which AVF is Best? Speaker: Mohamad Hussain, MD, PhD | | **08:48 AM - 08:58 AM** | [ Criteria and Predictors for Maturation](#thu0848am) The presentation will outline the key anatomic and functional features associated with favorable fistula creation and maturation. It will provide a framework for access selection and surgical planning for durable fistula creation and use. **Learning Objectives** - At the conclusion of this session, participants will be able to understand the key anatomic factors favoring arteriovenous fistula maturation. - At the conclusion of this session, participants will be able to apply a framework for artery and vein selection for fistula creation and cannulation.. Speaker: Jason Wagner, MD, FACS, FSVS | | **08:59 AM - 09:09 AM** | The Immature AVF: Methods to Induce Maturation Speaker: Yana Etkin, MD | | **09:10 AM - 09:20 AM** | Endo AVF's - The Current Evidence and Role Speaker: Ahmed Abdel Aal, MD, PhD | | **09:21 AM - 09:31 AM** | Q&A Panel Discussion Panelists: Ahmed Abdel Aal, MD, PhD; Yana Etkin, MD; Mohamad Hussain, MD, PhD; Adina Voiculescu, MD; Jason Wagner, MD, FACS, FSVS | | **09:32 AM - 09:52 AM** | [ Debate: EndoAVF is Done vs Surgical Access Deserts](#thu0932am) What is the role for Endo-AVFs. **Learning Objectives** - Appreciate surigcal success. - Appreciate EndoAVF success. Moderator: Dirk Hentschel, MD Panelists: Robert Shahverdyan, MD, PhD; Ahmed Abdel Aal, MD, PhD; Monnie Wasse, MD; Mohamad Hussain, MD, PhD; Surendra Shenoy, MD | | **09:53 AM - 10:23 AM** | Break | | **AV GRAFTS** | | **10:24 AM - 10:34 AM** | AV Graft Materials and Configurations Speaker: Jeffrey Lawson, MD, PhD | | **10:35 AM - 10:45 AM** | HeRO Graft - Pros and Cons Speaker: Stephen Hohmann, MD | | **MANAGEMENT OF ACCESS COMPLICATIONS** | | **10:46 AM - 10:56 AM** | [ Management of HAIDI: Which Therapy in Which Stage?](#thu1046am) Pathophysiology of HAIDI, staging of HAIDI and management of HAIDI based on both stage and pathophysiology. **Learning Objectives** - Understand the pathophysiology and staging. - Tailoring of the management options on a case by case basis. Speaker: Yael Vin, MD | | **10:57 AM - 11:07 AM** | [ Preventing HAIDI (Hemodialysis Access Induced Distal Ischemia)](#thu1057am) How to prevent the devastating outcome of HAIDI (Hemodialysis Access Induced Distal Ischemia) Speaker: Robert Shahverdyan, MD, PhD | | **11:08 AM - 11:14 AM** | Q&A Panel Discussion Panelists: Stephen Hohmann, MD; Jeffrey Lawson, MD, PhD; Robert Shahverdyan, MD, PhD; Yael Vin, MD | | **11:15 AM - 11:35 AM** | Break | | **11:36 AM - 11:46 AM** | High Flow Access Management: Surgical Speaker: John Ross, MD | | **11:47 AM - 11:57 AM** | [ Surgical and Endovascular Management of Aneurysms in AVF's](#wed1147am) Learn when and how to manage true aneurysms of primary AVFs. Demonstrate some of the surgical techniques in repairing aneurysms of arteriovenous fistulas. **Learning Objectives** - Identify the physical exam findings and access characteristics that lead to the decision to repair an aneurysm. - Learn surgical techniques to repair aneurysm of primary arteriovenous fistulas. Speaker: John Lucas, MD | | **11:58 AM - 12:03 PM** | Surgical and Endovascular Management of Pseudoaneurysms in AV Grafts Speaker: Tristen Chun, MD | | **12:04 PM - 12:09 PM** | Q&A Panel Discussion Panelists: Tristen Chun, MD; John Lucas, MD; John Ross, MD | | **12:10 PM - 12:40 PM** | The Henry Keynote Lecture — Vascular Access: The Story of a Specialty (from a Specialist) Speaker: Surendra Shenoy, MD, PhD | | **12:40 PM - 01:40 PM** | [ Lunch Symposium - Unwrapping WRAPSODY: Data, Durability, Decisions.](#thuMerit) This satellite lunch symposium will review recent clinical and real‑world evidence on the WRAPSODY® Cell‑Impermeable Endoprosthesis, with a focus on data published and presented over the past 12–24 months. Expert faculty will translate durability findings, core lab insights, and case experience into practical considerations for contemporary hemodialysis access management. Speakers: Dheeraj Rajan, MD, FRCPC, FSIR, FACR; Ari Kramer, MD Sponsored by: Merit Medical Systems, Inc | | **AV ACCESS MAINTENANCE** | | **01:40 PM - 01:50 PM** | Access Surveillance - Optimal Methods Speaker: Andrea Lubitz, MD, MPH | | **01:51 PM - 02:01 PM** | Biology of Intimal Hyperplasia and Strategies for Prevention Speaker: Sanjay Misra, MD | | **02:02 PM - 02:12 PM** | Covered Stents at the Venous Anastomosis: First Line or Last Line? Speaker: Charles Kim, MD | | **02:13 PM - 02:23 PM** | [ Drug-Coated Balloons - Most Recent Data](#thu0213pm) This presentation will update participants on the most recent published data related to drug eluting balloons and their applications in vascular access maintenance. We will cover most recent data from pivotal trials and summarize findings of recent meta-analyses. **Learning Objectives** - At the conclusion of this presentation, participants will be able to apply most recent data about drug eluting balloons to decisions about device selection for interventions in AV access interventions. Speaker: Gordon McLennan, MD, FSIR | | **02:24 PM - 02:34 PM** | [ Central Venous Stenosis - When to Treat and How?](#thu0224pm) Update presentation on the best practices to treat central venous stenosis. **Learning Objectives** - Discuss indications, devices, technical details. - Discuss how to avoid complications. Speakers: Marcelo Guimaraes, MD, MBA, CPE, FSIR; Alexander Ushinsky, MD | | **02:35 PM - 02:45 PM** | [ Bare vs Covered Stents for Central Veins: What to Use?](#thu0235pm) A review of when to use bare stents, and when to use covered stents for Thoracic Central Vein Obstruction (TCVO) in dialysis patients. **Learning Objectives** - Recognize the limited use of bare stents in the thoracic central veins. - Understand the potential for using covered stents in the thoracic central veins. Speaker: Bart Dolmatch, MD, FSIR | | **02:46 PM - 02:54 PM** | Q&A Panel Discussion Panelists: Bart Dolmatch, MD, FSIR; Charles Kim, MD; Andrea Lubitz, MD, MPH; Gordon McLennan, MD, FSIR; Sanjay Misra, MD; Alexander Ushinsky, MD | | **02:55 PM - 03:10 PM** | Debate: Venous Anastomosis Stenosis: POBA, DCB, Stent, Stent Graft, Revise? Moderator: Dheeraj Rajan, MD, FRCPC, FSIR, FACR Panelists: Ari Kramer, MD; Stephen Hohmann, MD; Ahmed Abdel Aal, MD, PhD; Dirk Hentschel, MD; Neghae Mawla, MD, FASDIN | | **03:11 PM - 03:41 PM** | Break | | **03:42 PM - 03:50 PM** | [ Declotting AV Grafts: How I Do It (Vascular Surgeon)](#thu0342pm) Declotting of arteriovenous grafts from a surgical perspective. **Learning Objectives** - How to do an open declot of an arteriovenous graft. - Understanding what are the limitations and advantages of open declots. Speaker: John Lucas, MD | | **03:51 PM - 03:59 PM** | Declotting AV Grafts: How I Do It (Interventional Nephrologist) Speaker: Neghae Mawla, MD, FASDIN | | **04:00 PM - 04:08 PM** | [ Declotting AV Grafts: How I Do It (Interventional Radiologist)](#thu0400pm) Technical details on graft declots using IR techniques will be discussed. **Learning Objectives** - To understand the technique used for declotting AVG used for dialysis using interventional radiologic techniques. - To understand potential complications using IR techniques in graft declots. Speaker: Charles Ray, MD, PhD | | **04:09 PM - 04:15 PM** | Q&A Panel Discussion Panelists: John Lucas, MD; Neghae Mawla, MD, FASDIN; Charles Ray, MD, PhD | | **04:16 PM - 04:26 PM** | Stent Venous Anastomosis - Consult with Vascular Surgeon or Just Do It? Speaker: John Aruny, MD | | **04:27 PM - 04:37 PM** | [ Stent vs HeRO for Arm Swelling Due to Central Stenosis](#thu0427pm) I will share data from our institution and others comparing outcomes when arm swelling due to central vein stenosis ipsilateral to an AV access is treated with central vein stenting versus HeRO graft conversion. **Learning Objectives** - Learn the technique for two-stage HeRO graft implantation. - Familiarize audience with comparitive patency data between HeRO grafts and central venous stents. Speaker: Brendan Cline | | **04:38 PM - 04:48 PM** | Impact of Hypotension on AV Access Speaker: Jose Navarrete, MD | | **04:49 PM - 04:59 PM** | Q&A Panel Discussion Panelists: John Aruny, MD; Brendan Cline; Jose Navarrete, MD | | **INNOVATION/BEST ABSTRACTS SESSION 2** | | **05:00 PM - 05:07 PM** | Xeltis aXess: Transforming Polymer into Living Tissue Speaker: Jason Wagner | | **05:08 PM - 05:15 PM** | One-year Reintervention Outcomes Following Use of a Cell-Impermeable Endoprosthesis vs. Angioplasty for De Novo vs Restenotic Lesions Speaker: Dheeraj Rajan, MD, FRCPC, FSIR, FACR | | **05:16 PM - 05:23 PM** | [ Self-repair of Acellular Tissue Engineered Vessels (ATEV™) after Cannulation for Dialysis Access](#thu0516pm) Acellular Tissue Engineered Vessels (ATEVs) demonstrated sustained structural integrity, effective healing after repeated cannulation, and enhanced resistance to infection compared with ePTFE grafts, which exhibited progressive wall deterioration and more severe pathological changes. The predominance of lower grade injury in ATEVs, together with evidence of active cellular repair and bacterial containment, highlights their regenerative capacity and ability to support improved host defenses. These findings support ATEVs as a durable, self-repair and infection-resistant vascular access option for long term hemodialysis. **Learning Objectives** - Participants will be able to evaluate and compare current conduits for vascular access through the scope of wall integrity and active tissue repair after repeated cannulations. - Participants will be introduced to and will evaluate the Acellular Tissue Engineered Vessel (ATEV) as a biocompatible conduit with enhanced resistance to infection when compared to synthetic ePTFE. Speakers: Maisha Clancy, MA; Juan Wang, PhD | | **05:24 PM - 05:31 PM** | Early Detection of Hemodialysis Access Stenosis Using Contact-Free Optical Monitoring and Predictive Modeling Speakers: Lalathaksha Kumbar, MD, MBA; Hagay Drori, BSc, ME | | **05:35 PM - 05:50 PM** | VASA Member Business Meeting | | **05:45 PM - 07:00 PM** | Reception | | FRIDAY, MAY 22, 2026 | |---| | **07:00 AM - 08:00 AM** | Breakfast | | **PERITONEAL DIALYSIS** | | **08:01 AM - 08:11 AM** | Patient Considerations for PD: Pros and Cons vs HD Speaker: Stephen Hohmann, MD | | **08:12 AM - 08:20 AM** | How I Do It: PD Catheter Insertion (Surgery) Speaker: Karen Woo, MD | | **08:21 AM - 08:29 AM** | How I Do It: PD Catheter Insertion (Interventional Nephrology) Speaker: Mohamed Sheta, MD | | **08:30 AM - 08:38 AM** | How I Do It: PD Catheter Insertion (Interventional Radiology) Speaker: David Strain, MD | | **08:39 AM - 08:45 AM** | Q&A Panel Discussion Panelists: Stephen Hohmann, MD; Karen Woo, MD; Mohamed Sheta, MD; David Strain, MD; Charles Kim, MD | | **08:46 AM - 09:06 AM** | Debate: Fistula First or PD Catheter First? Moderator: Mitch Henry; Panel | | **HEMODIALYSIS CVC'S** | | **09:07 AM - 09:17 AM** | When the IJ's are Gone, Where do we Go? Time for a New Paradigm Speaker: Michael Tal, MD | | **09:18 AM - 09:28 AM** | When ALL the Veins are Gone: Where to go? Speaker: Charles Kim, MD | | **09:29 AM - 09:39 AM** | [ Catheter Locks, Dressings, and Coatings: What Works?](#fri0929am) This session provides a high-level review of the current evidence regarding catheter locks, specialized dressings, and antimicrobial coatings in the prevention of CRBSI and catheter dysfunction. We will evaluate which technologies offer a statistically significant benefit in the hemodialysis population versus those that remain primarily theoretical. Attendees will leave with a clear, evidence-based framework for selecting the most effective infection-prevention strategies for their clinical practice. **Learning Objectives** - Evaluate the clinical efficacy of various catheter lock solutions, dressings, and antimicrobial coatings in reducing catheter-related bloodstream infections (CRBSI) and improving patency in hemodialysis patients. - Develop an evidence-based approach to selecting specific catheter-related technologies by distinguishing between statistically significant clinical benefits and theoretical manufacturer claims. Speaker: Neal Viradia, MD, MPH | | **09:40 AM - 09:46 AM** | Q&A Panel Discussion Panelists: Charles Kim, MD; Neal Viradia, MD, MPH; David Strain, MD | | **09:47 AM - 10:17 AM** | Break | | **MISC AV ACCESS TOPICS** | | **10:18 AM - 10:28 AM** | Post Transplant Access Management: Keep or Ligate? Speaker: Surendra Shenoy, MD, PhD | | **10:29 AM - 10:39 AM** | [ Nerve Blocks for Access Creation and Maintenance](#fri1029am) This presentation will discuss the benefit of nerve blocks in dialysis creation, the types of blocks used, and block adjuncts for both access creation and maintenance. **Learning Objectives** - Learn the benefit of nerve blocks. - Learn techniques for nerve blocks. Speaker: Libby Weaver, MD | | **10:40 AM - 10:50 AM** | Flow Volume Measurements Speaker: Greg Martens, MD | | **10:51 AM - 11:01 AM** | Frailty and Multi-Morbidity Speaker: Andrea Lubitz, MD, MPH | | **11:02 AM - 11:12 AM** | [ ESKD Life Plan and Access Plan: Surgery Perspective vs Practice Bldg](#fri1102am) Discuss the National Kidney Foundation ESKD Life - Plan as it relates to access surgery. **Learning Objectives** - At the conclusion of this session, participants will be able to evaluate the patient’s current medical situation, their current and future life goals, their preferences, social support, functional status, logistic and other practical feasibilities when planning access surgery. Speaker: Brittany Aicher, MD | | **11:13 AM - 11:23 AM** | [ Access for Morbid Obesity](#fri1113am) Morbid obesity presents unique anatomical, hemodynamic, and technical challenges for hemodialysis vascular access creation and maintenance. This presentation reviews the evidence-based strategies for access planning in this population, including vessel mapping considerations, preferred access configurations, and the role of endovascular alternatives. Special attention will be given to perioperative risk stratification and outcomes data specific to patients with a BMI ≥ 40. Attendees will leave with a practical framework to guide individualized access decisions in morbidly obese patients. **Learning Objectives** - Identify the anatomical and physiological factors unique to morbid obesity that influence vascular access selection and surgical planning for hemodialysis. - Apply an evidence-based decision framework to optimize access type, site selection, and perioperative management in morbidly obese hemodialysis patients. Speaker: Carlos Hinojosa, MCs | | **11:24 AM - 11:34 AM** | Q&A Panel Discussion Panelists: Brittany Aicher, MD; Carlos Hinojosa, MCs; Greg Martens, MD; Andrea Lubitz, MD, MPH; Surendra Shenoy, MD, PhD; Libby Weaver, MD | | **DEVICE DEVELOPMENT** | | **11:35 AM - 11:45 AM** | From Back Table to Bedside: Navigating the Gauntlet from Concept to Commercialization of Dialysis Access Devices Speaker: Robert Lee, MD | | **11:46 AM - 11:56 AM** | [ From Clinical Provider to Industry: Device Idea to Clinical Trials and Beyond](#fri1146pm) I will share my story from clinical practice, identifying a clinical need, device development, regulatory affairs, to clinical trials, and acquisition. At the conclusion of this session, participants will be able to recall general steps to take a device from bench to clinical trials. Speaker: Shawn Gage, PA-C | | **11:57 AM - 12:07 PM** | How do physicians become innovators? Speaker: Jeffrey Lawson, MD, PhD | | **12:08 PM - 12:14 PM** | Q&A Panel Discussion Panelists: Shawn Gage, PA-C; Jeffrey Lawson, MD, PhD; Robert Lee, MD | | **12:15 PM - 01:15 PM** | Lunch | | **TOP ABSTRACTS** | | **01:16 PM - 01:23 PM** | [ Comparative Effectiveness of Drug-coated Balloons in Dysfunctional Hemodialysis Circuits in Medicare Beneficiaries](#fri0116pm) This comparative effectiveness study utilizes Medicare data to report on real world outcomes of drug-coated vs. uncoated balloon angioplasty for arteriovenous fistulas. **Learning Objectives** - Describe real-world clinical effectiveness outcomes from drug-coated balloon angioplasty. - Describe real-world clinical safety outcomes from drug-coated balloon angioplasty. Presenter: Helena Smith, MD | | **01:24 PM - 01:31 PM** | [ Remodeled Cephalic Arch Geometry Promotes Disturbed Flow at Pre-maturation Flow Rates in Hemodialysis Patients](#fri0124pm) In this study, we describe a novel millifluidic model of the cephalic arch that enables us to describe internal hemodynamics at clinically relevant flow rates. We employ these models to 1) calculate venous wall shear stress (WSS), and 2) calculate streamline angle as a metric of flow disturbance. We report that hemodynamic flow disturbance arises in the cephalic arch as a consequence of patient vein geometry and elevated flow rates. Ultimately, we show that remodeled geometry and elevated flow rates create a hemodynamic environment conducive to vascular complications and subsequent access failure. **Learning Objectives** - At the conclusion of this presentation, participants will understand how fistula flow rates promote disturbed flow within the cephalic arch. Presenters: Dylan Cook, Phd(c); Mary Hammes, DO | | **01:32 PM - 01:39 PM** | [ Surgical Management of Cephalic Arch Stenosis via Cephalic Vein Transposition: A Cost-Effective Strategy for Preserving Fistula Patency](#fri0132pm) We present our experience performing surgical treatment-cephalic vein transposition-for management of Cephalic Arch Stenosis on 30 patients on a 6 years period. The analysis and follow up shows consistent clinical outcomes, patency rates and cost-effectivenesss than surpass those reported for endovascular procedures. **Learning Objectives** - At the conclusion of this session participants will be able to evaluate the role of surgical management of Cephalic Arch Stenosis via Cephalic Vein Transposition and compare its consistent results with those reported for endovascular procedures. Presenter: Alexis Garcia-Lopez, MD | | **01:40 PM - 01:47 PM** | [ The Utility of Forearm Loop Arteriovenous Grafts as Part of a Dialysis Access Life Plan](#fri0140pm) This study evaluates the role of forearm loop arteriovenous grafts (flAVG) in hemodialysis access within the context of modern, patient-specific access planning. In a single-institution retrospective analysis, flAVGs demonstrated significantly faster time to cannulation and fewer procedures required for maturation compared to other access types, though they required more interventions to maintain patency and had higher abandonment rates. Despite these trade-offs, overall patency was comparable to other configurations, suggesting that forearm grafts are not inferior as previously reported. These findings support incorporating flAVGs into individualized dialysis “life plans,” particularly for patients needing rapid access while preserving future vascular sites. Presenter: Thomas Coleman, MD | | **01:48 PM - 01:55 PM** | [ Association of Multimorbidity and Frailty with Vascular Access Outcomes](#fri0148pm) Multimorbidity and frailty each play an important role in vascular access outcomes, but their combined effect reveals a more complete picture of patient risk. In this retrospective cohort analysis, we evaluated the association of both these factors, individually and in combination, with hemodialysis vascular access (HDVA) and access abandonment. Patients with both high multimorbidity and frailty experienced the highest rates of access abandonment and worsening outcomes across groups. This highlights the importance of considering the two aspects together to better inform clinical decision-making and risk assessment. **Learning Objectives** - Participants will be able to understand how multimorbidity and frailty independently and jointly influence hemodialysis vascular access abandonment and patient mortality. - Participants will be able to recognize the value of considering multimorbidity in combination with frailty to guide shared decision-making and optimize patient outcomes for vascular access creation. Presenter: Sahana Ravishankar, BA | | **GLOBAL DIALYSIS ACCESS FORUM** | | **01:56 PM - 02:06 PM** | Updates in Dialysis Access Care in Japan Speaker: Toshihide Naganuma, MD, PhD | | **02:07 PM - 02:17 PM** | VAS – Dialysis Access in European Nations Speaker: Robert Shahverdyan, MD, PhD | | **02:18 PM - 02:28 PM** | Current Situation of CKD, RRT, and Vascular Access Program in the South East Asia Pacific Region & India Speaker: Sanjiv Jasuja, MD, DNB, MNAMS, FIMSA | | **02:29 PM - 02:39 PM** | [ Necessity: Mother of (Reverse) Innovations: Vascular Access Lessons from the Asia-Pacific](#fri0229pm) Status and trends of renal replacement therapy and vascular access strategies in Asia Pacific region. The region being very heterogeneous, I shall concentrate on India, which has a very active vascular access program with unique problems and solutions which could be in variance with the west. **Learning Objectives** - Peep into the current situation of CKD, RRT and the Vascular Access program in the Asia Pacific region, especially India. - There are likely to be some innovations and reverse innovations, which should be worth notable for the American audience. Speakers: Jeyaraj Balasubramaniam, MD, DM, FRCP, FASN; Sanjiv Jasuja, MD, DNB, MNAMS, FIMSA | | **02:40 PM - 02:50 PM** | VASA – Problems and Initiative in Vascular Access Care in Latin American Countries Speaker: Carlos Hinojosa, MD | | **02:51 PM - 03:01 PM** | [ USA State of Dialysis Access](#fri0251pm) Dialysis access in the US is under government control. However, no regulatory guidelines direct quality expectations for access surgeons. Fiscal incentives and clinical outcomes are not aligned. The variety of anatomic AVF solutions, as well as existing and novel non-autogenous conduit options present cannulators in dialysis units with unsolvable tasks of cognition. **Learning Objectives** - Dialysis access use is part of a complex medical system. - Access success hinges on the weakest link. Speaker: Dirk Hentschel, MD | | **03:02 PM - 03:11 PM** | Discussion | | **03:12 PM - 03:17 PM** | Closing Remarks Speaker: Charles Kim, MD | ## Schema ```json { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://vasamd.org" }, { "@type": "ListItem", "position": 2, "name": "Symposium", "item": "https://vasamd.org/events/symposium" }, { "@type": "ListItem", "position": 3, "name": "Symposium Agenda", "item": "https://vasamd.org/events/symposium/symposium-agenda" } ] } ``` ```json { "@context": "https://schema.org", "@type": "Organization", "@id": "https://vasamd.org/events/symposium/symposium-agenda#organization2", "name": "Vascular Access Society of the Americas", "alternateName": "Agentis", "legalName": "Agentis Management", "email": "info@vasamd.org", "url": "https://vasamd.org", "telephone": "(859) 977-7457", "foundingDate": "2004-01-01", "logo": "https://vasamd.org//images/gsd.png", "image": "https://vasamd.org//images/gsd.png", "address": { "@type": "PostalAddress", "streetAddress": "1024 Capital Center Drive, Suite 205, Frankfort, Kentucky", "postalCode": "40601" } } ``` ```json { "@context": "https://schema.org", "@type": "Article", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://vasamd.org/events/symposium/symposium-agenda" }, "headline": "2026 Symposium", "description": "2026 Symposium The Vascular Access Society of the Americas invites you to participate as an exhibitor at the 2026 Vascular Access for Dialysis Symposium, May 20-22, 2026 at the Hilton Salt Lake City Center in Salt Lake City, Utah. This Symposium is designed for all transplant, vascular and general surgeons, nephrologists, interventional radiologists and nephrologists, nurses and allied health professionals who are interested in the management of vascular access. The VASA Symposium is an excellent opportunity for your company to showcase its products and services to a multidisciplinary audience committed to advancing dialysis patient care. The Program Committee is busy planning an excellent scientific meeting that will include: State-of-the-art lectures covering all major areas in dialysis access Diverse multi-disciplinary faculty including prominent international speakers representing Europe, Asia, Canada, South America, & Japan 40 scientific abstract presentations Vascular access nursing and allied health New devices and technologies Video presentations Thank you for attending the 2026 VASA Symposium in Salt Lake City! We hope it was not only an great educational experience for you, but an opportunity to reconnect with your peers! Flickr is an inclusive global community of photography enthusiasts and the best place for inspiration, connection, and sharing! Follow VASA on Flickr! Photo Gallery ​ WEDNESDAY, MAY 20, 2026 — ALLIED HEALTH PROGRAM 07:00 AM - 07:30 AM Breakfast 07:30 AM - 07:35 AM Welcome Speaker: Debbie Brouwer-Maier, RN, CNN 07:35 AM - 07:50 AM  ESKD Life Plan and Access Plan The 2019 KDOQI Vascular Access Guidelines are based on an individualized modality plan and dialysis access plan to support the PD or HD for patients in the later stages of CKD. The dialysis access process of care is based on the Life Plan and supporting Dialysis Access Plan. The KDOQI guideline interpretation and implementation are based on the individual patient's ESKD Life-Plan and Dialysis Access Plan. Learning Objectives Discuss the progress to create and update a patient's ESKD Life-Plan and Dialysis Access Plan. Discuss the KDOQI Guidelines impetration and implementation are based on the patient's ESKD Life-Plan and Dialysis Access Plan. Speaker: Debbie Brouwer-Maier, RN, CNN {show usergroup="OnDemand"} Download Presentation {/show} 07:50 AM - 08:20 AM  AV Access Creation, HD Catheter and PD Placement Basics of AVF and AVG creation, HD catheter placement and PD catheter placement. Learning Objectives Learn how the different access techniques are performed. Learn the problems related to each access modality. Speaker: John Lucas, MD {show usergroup="OnDemand"} Download Presentation {/show} 08:20 AM - 09:05 AM Patient Models at Stations: 1-min Check with Patients, Physical Exams Speakers: John Lucas, MD; Dirk Hentschel, MD; Jacquelyn N. Hall, CCHT, VAC 09:05 AM - 09:20 AM Break 09:20 AM - 09:50 AM  VASA Toolkit for Show & Tell Dialysis Access Devices for Nurses Learning Objectives Understand tunneled catheter design and function. Understand graft for cannulation. Speakers: John Lucas, MD; Dirk Hentschel, MD; 09:50 AM - 10:20 AM  Cannulation Stations Hands-on stations for demostration of various cannulation techniques with time for the partipants to do a return demonstration. Learning Objectives Demonstration of the proper cannulation methods using a hands-on model. Discussion of the proper Rope Ladder or Buttonhole cannulation techniques. Speakers: Debbie Brouwer-Maier, RN, CNN; Amber Parker; Crystal Fahner 10:20 AM - 11:15 AM  ANNA Intermountain Chapter Collaboration Session: 360 degree Care of the Nephrology Patient The three speakers will share the presentation, focusing on the journey of a CKD patient as they approach starting dialysis and on the role of the nephrology nurse/care team. They will include issues like anemia and other complications of CKD that impact the process of care for the Life Plan and Dialysis Access Plan. They may use a case presentation or a collection of case presentations. Learning Objectives Outline the distinct roles of nursing professionals in the care of persons requiring kidney care. Using case studies with audience participation, review the interventions used to initiate and maintain kidney care. Speakers: Kristin Larson, AGNP-BC, CNN, FANNA; Kennadi Lower, RN, BSN; Melanie Kreitzer, BSN, RN, CNN 11:15 AM - 11:30 AM Break WEDNESDAY, MAY 20, 2026 — PLENARY & GENERAL SESSIONS 11:30 AM - 12:00 PM  The Holland Keynote Lecture: Best Cannulation Practices are Achievable Compare current US cannulation to advancements achived outside the US, such as POCUS for cannulation mapping and real-time cannulation, different needle gauges and designs, standardized cannulation guidelines, and training. Call to action to improve the US standard of care by adopting more advanced cannulation techniques. Learning Objectives Discuss the current state of cannulation in the US. Discuss advancements commonly used outside the US including means to implement change in the US clinical practice. Speaker: Debbie Brouwer-Maier, RN, CNN {show usergroup="OnDemand"} Download Presentation View Presentation {/show} CANNULATION 12:00 PM - 12:10 PM  Needle Designs and Impact on Cannulation Expand on the various needle designs currently available in the US. Review the design elements that impact the vascular access and how improved designs can help to decrease known issues with the commonly US utilized metal needle design. Learning Objectives Discuss the design elements of the various needles and the clinical impact of the design elements. Speaker: Debbie Brouwer-Maier, RN, CNN {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 12:11 PM - 12:19 PM  Eradicating Area Cannulation / Dead Space Between Dialysis Needles Emphasizing the importance of early site rotation. Show the detrimental effects of area cannulation. Learning Objectives Learn to start rope and ladder cannulation early on. Learn to periodically look for additional sites for cannulation. Speaker: John Lucas, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 12:20 PM - 12:28 PM Covered Stent Grafts in Cannulation Segment Speaker: Alexander Ushinsky, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 12:29 PM - 12:35 PM Q&A Panel Discussion Panelists: Debbie Brouwer-Maier, RN, CNN; John Lucas, MD; Alexander Ushinsky, MD {show usergroup="OnDemand"} View Presentation {/show} 12:35 PM - 01:35 PM Lunch Symposium - Dialysis Access Decisions: Where Data, Guidelines, and Patient Needs Align Speakers: Stephen Hohmann, MD; Yana Etkin, MD Sponsored by: Gore & Associates USRDS 01:35 PM - 01:45 PM 2025 USRDS: A Fundamental Failure of Systems of Access Placement in the US Speaker: Victoria Teodorescu, MD, MBA, RVT {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 01:46 PM - 01:56 PM  Progress and Paradox: What the 2025 USRDS Report Reveals About Vascular Access The 2025 USRDS report reveals a paradox in dialysis access care: improved outcomes once access is established, yet persistently high catheter use at initiation. Declines in abandonment and infection rates highlight advances in access management, but failures in predialysis planning remain widespread. This presentation examines this disconnect and its implications for enhancing future access strategy. Learning Objectives Evaluate contemporary trends in vascular access outcomes from the USRDS 2025 report, including improvements in access durability and infection rates among prevalent hemodialysis patients. Apply risk-based, multidisciplinary strategies to reduce catheter dependence at dialysis initiation. Speaker: Robert Lee, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 01:57 PM - 02:07 PM How can we get Nephrologists to Refer Patients for Access Earlier? Speaker: Jose Navarrete, MD 02:08 PM - 02:18 PM  Artificial Intelligence will Save the Day (or Not) Artificial Intelligence (AI) is increasingly influencing vascular access care, with applications spanning device selection, insertion, and complication prevention. Advanced analytics and real-time decision support offer the potential to improve appropriateness of device utilization, enhance vessel preservation—particularly in patients with kidney disease—and reduce complications such as thrombosis and infection, while reinforcing adherence to evidence-based practices and value-based care frameworks. Despite this promise, adoption remains constrained by limitations in data quality, workflow fragmentation, interoperability challenges, and concerns related to bias and transparency, with many solutions lacking rigorous prospective validation. Absent robust governance structures and meaningful clinician engagement, implementation may be suboptimal, underscoring the necessity for AI to augment—rather than replace—clinical judgment. This session will provide a balanced and pragmatic assessment of AI in vascular access, emphasizing current applications, inherent limitations, and strategies for responsible, scalable integration into clinical practice. Speaker: Karthik Ramani, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 02:19 PM - 02:29 PM  ESRD Networks: Is CMS oversight effective? Provide a brief overview of the history of the quality measures related to vascular access in the ESRD Quality Incentive Program (QIP). Review the current vascular access quality measure to include overall dialysis facility performance and payment penalties enforced by CMS. Conclude with the patient and provider critiques of this aspect of the ESRD QIP. Learning Objectives At the conclusion of this session, participants will understand the current quality measure included in the ESRD QIP covering vascular access. At the conclusion of this session, participants will understand what is missing from the current ESRD QIP related to vascular access. Speaker: Andrew D. Howard, MD, FACP {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 02:30 PM - 02:40 PM Q&A Panel Discussion Panelists: Victoria Teodorescu, MD, MBA, RVT; Robert Lee, MD; Jose Navarrete, MD; Karthik Ramani, MD; Andrew D. Howard, MD, FACP {show usergroup="OnDemand"} View Presentation {/show} 02:50 PM - 03:20 PM Break ACCESS PARADIGMS 03:21 PM - 03:31 PM  Not a One-and-Done: Role of Surgeons in Longitudinal Access Surveillance and Maintenance My message will be that continued longitudinal followup of our patients after access creation and maturation is critical to avoid complications and ensure happy patients and referral sources. Learning Objectives Participants will be able to identify the four critical goals to be addressed at each visit. Participants will be able to apply several techniques to use if complications arise. Speaker: Karl Illig, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 03:32 PM - 03:42 PM  What Does it Take to Improve Dialysis Access Outcomes? Dialysis access outcomes fall short of many other procedural types. Reasons for this will be discussed and potential remedies will be offered. Speaker: Monnie Wasse, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 03:43 PM - 03:53 PM Shared Decision Making - How? Speaker: Karen Woo, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 03:54 PM - 04:00 PM Q&A Panel Discussion Panelists: Karl Illig, MD; Monnie Wasse, MD; Karen Woo, MD {show usergroup="OnDemand"} View Presentation {/show} 04:01 PM - 04:21 PM DEBATE: OBL Vascular Access Centers vs Hospitals: The Good and the Bad Moderators: Stephen Hohmann, MD; John Ross, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 04:22 PM - 04:52 PM  Keynote Lecture - Toward an Unlimited Organ Supply: Translating Xenotransplantation to the Clinic This session will review the scope and clinical consequences of organ shortage in kidney transplantation. The scientific rationale, recent clinical progress, and ongoing challenges of xenotransplantation as a potential solution to donor organ scarcity will be discussed. Participants will learn that the use of genetically engineered porcine organs for transplantation represents a scientifically advancing strategy to reduce waitlist mortality and address the persistent shortage of transplantable organs Speaker: Ragnar Palsson, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} INNOVATION/BEST ABSTRACTS SESSION 1 04:53 PM - 05:03 PM  Early Fistula Maturation and Cannulation Outcomes of the VASQ U.S. Post-Market Randomized Controlled Study at an Ambulatory Surgery Center Introduction: The clinical benefit of a permanently implanted nitinol scaffold to provide extravascular support for fistulas is being evaluated in the U.S. via a post-market, multicenter, randomized controlled trial. Here, initial outcomes from a single participating center will be presented. Methods: The study plans to enroll 300 extravascular supported (ES-AVFs) and unsupported (Control) fistulas, randomized 1:1, and compare the primary endpoint of time to cannulation success (confirmed via three-fourths successful two-needle cannulation over 30-day period). Additional data will be analyzed for 5-week cannulation readiness (referral for cannulation by the surgeon), primary failure (abandoned prior to maturation), interventions and patency over a 1-year follow-up period. All radiocephalic (RCF) and brachiocephalic (BCF) patients that consent will be included over multiple centers provided a superficial is not anticipated, without known central venous stenosis and 80 years old or younger. Results: This single site has enrolled 28 patients (13 ES-AVF and 15 Control) with sufficient follow-up data to assess maturation in 26 patients (12 ES-AVF and 14 Control). ES-AVF patients include 8 BCF and 5 RCF, and Control patients include 9 BCF and 6 RCF with similar demographics and comorbidities. Unassisted maturation was higher for ES-AVF patients at 41.7% vs 21.4% for control (Figure 1). Higher unassisted maturation rates correlated with higher 5-week cannulation readiness for ES-AVF patients at 33.3% vs 21.4% for Control patients. Similar primary failure rates were observed for ES-AVF at 25.0% vs 21.4% for controls. Fewer ES-AVF patients have required procedures to support maturation at 33.3% vs 64.3% for Control patients (Figure 1). The difference was largely driven by fewer angioplasties to assist maturation for ES-AVF patients who have required 0.08 per-patient vs 0.43 per-patient for controls (Figure 2). No angioplasties were performed due to stenosis for ES-AVF patients vs 70.0% of control patient angioplasties were to treat a clinically significant stenosis. ES-AVF offered fewer cannulation challenges with dialysis centers reporting “Difficult to Cannulate” for ES-AVF patients at a rate of 0.25 events per-patient vs 0.57 events per patient for controls. Additionally, ES-AVF patients reported no infiltrations to date vs 0.35 infiltrations per-patient for controls (Figure 2). Conclusion: The initial experience at this participating center in the VASQ U.S. Post-Market Randomized-Controlled confirms the early clinical benefits of ES-AVF to improve maturation rates with fewer interventions. ES-AVF appears to have a lower risk of early stenosis requiring angioplasty to mature fistulas as well as complications due to cannulation. Continued enrollment into the study will help elucidate any statistical differences between the two groups as the sample size grows. Speaker: Dion Franga, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 05:04 PM - 05:11 PM  Preserving Arteriovenous Access Circuits: 12-Month Results in Real-World Patients Following Kinetic Endovascular Micro-Incision Creation Prior to Plain Balloon Angioplasty for Treatment of Arteriovenous Access Dysfunction The 12-month results from the FLEX FIRST AV Registry is a prospective, multi-center, real-world study evaluating the FLEX Vessel Prep™ System in patients with dysfunctional hemodialysis access. The study enrolled 130 patients across four U.S. centers, representing a diverse, high-risk population reflective of real-world clinical practice. The results demonstrated a compelling combination of safety, durability, and performance across complex lesion type by utilizing FLEX Vessel Prep and Kinetic Endovascular Micro-incision Creation (KEMIC) technology as a differentiated mechanical vessel preparation strategy. Learning Objectives At the conclusion of this session, participants will be able to evaluate current standard of care algorithms for arteriovenous fistula maintenance and consider incorporating vessel prep with KEMIC ahead of destination therapies to optimize outcomes. Participants will be able to apply real-world evidence to improve AV Access fistula durability. Speaker: Ari Kramer, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 05:12 PM - 05:19 PM  Initial Clinical Results of the Distal Staging Fistula in Catheter Dependent ESRD Patients AVF is the ideal vascular access for hemodialysis. However, many patients are not eligible for a fistula, The Distal device is used to create an endovascular radial-radial arterio-venous fistula (AVF) at the wrist. Increased flow and pressure from the Distal device fistula are transmitted through perforator veins into the cephalic vein. The cephalic vein responds with dilation, wall remodeling, and progressive enlargement. A secondary surgical AVF utilizing the enlarged cephalic vein is then performed. Conclusions: In summary, most subjects have experienced benefits or are on track for benefiting from the Distal procedure. These patients did not have adequate veins for surgical fistula creation prior to the Distal procedure; they did not lose a potential access site as a result of the Distal procedure; and they did not experience AEs associated with the Distal device or procedure. Speakers: Michael Tal, MD, MBA; Ari Kramer, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 05:20 PM - 05:27 PM  Initial Feasibility Study of SelfWrap-Assisted Arteriovenous Fistulas (SW-AVF) - A 54-Month Report Study results at 54 months. Learning Objectives Appreciate outcomes with and without juxta-anastomotic wrap. Speaker: Dirk Hentschel, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 05:28 PM - 05:35 PM  The VENOS-2 Early Feasibility Study: One Year Outcomes of the Velocity® Percutaneous Arteriovenous Fistula Hemodialysis initiation with an AVF and minimizing CVC contact time remain critical unmet needs for patients with ESRD. Commercially available percutaneous AVF (pAVF) devices have demonstrated safe and reliable access creation; however, their adoption has been limited by high reintervention rates, need for flow-diversion procedures to achieve target vein maturation, and requirement for specialized cannulation training, all factors that collectively prolong catheter dependence. These limitations are largely attributable to a distributed venous outflow pattern that dissipates flow across the deep venous system, reducing flow in the superficial cannulation zone where maturation is needed. The Velocity pAVF System (Venova Medical, Los Gatos, CA) is an implant-based device designed to replicate surgical AVF anatomy by directing arterial flow exclusively into the superficial venous system, while simultaneously shielding the juxta-anastomotic endothelium from turbulence, a principal driver of anastomotic stenosis. Speaker: Robert Shahverdyan, MD, PhD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 05:35 PM - 07:00 PM Reception & Poster Sessions THURSDAY, MAY 21, 2026 07:00 AM - 08:00 AM  Breakfast Symposium - Consistency from Creation through Cannulation with VasQ Extravascular Support Can stabilizing hemodynamic and mechanical variables of fistula failure help standardize AVFs from creation through cannulation? And what does that mean for the definition of AVF success? These are the questions providers across the vascular access care continuum wrestle with every day. If these questions resonate with you, don’t miss Beyond the OR: Consistency from Creation through Cannulation with speakers Dr. Robert Shahverdyan and Dr. Monnie Wasse. Speakers: Robert Shahverdyan, MD, PhD; Monnie Wasse, MD Sponsored by: Laminate Medical Technologies 08:00 AM - 08:05 AM Opening Remarks Speaker: Charles Kim, MD {show usergroup="OnDemand"} View Presentation {/show} 08:05 AM - 08:25 AM VASA Presidential Address Speaker: John Lucas, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} AUTOGENOUS AV FISTULAS 08:26 AM - 08:36 AM  Vein Mapping: Ultrasound vs Venography The presentation will outline the key features of two techniques—ultrasound and venography—used to evaluate a patient’s vessels prior to vascular access creation. It will compare the advantages and limitations of each method and propose a recommended best-practice assessment pathway. Learning Objectives At the conclusion of this session, participants will be able to understand the difference between two different techniques for vein mapping before arteriovenous fistula creation and will be able to select the most appropriate one based on patient specific factos. Speaker: Adina Voiculescu, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 08:37 AM - 08:47 AM Which AVF is Best? Speaker: Mohamad Hussain, MD, PhD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 08:48 AM - 08:58 AM  Criteria and Predictors for Maturation The presentation will outline the key anatomic and functional features associated with favorable fistula creation and maturation. It will provide a framework for access selection and surgical planning for durable fistula creation and use. Learning Objectives At the conclusion of this session, participants will be able to understand the key anatomic factors favoring arteriovenous fistula maturation. At the conclusion of this session, participants will be able to apply a framework for artery and vein selection for fistula creation and cannulation.. Speaker: Jason Wagner, MD, FACS, FSVS {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 08:59 AM - 09:09 AM The Immature AVF: Methods to Induce Maturation Speaker: Yana Etkin, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 09:10 AM - 09:20 AM Endo AVF's - The Current Evidence and Role Speaker: Ahmed Abdel Aal, MD, PhD 09:21 AM - 09:31 AM Q&A Panel Discussion Panelists: Ahmed Abdel Aal, MD, PhD; Yana Etkin, MD; Mohamad Hussain, MD, PhD; Adina Voiculescu, MD; Jason Wagner, MD, FACS, FSVS {show usergroup="OnDemand"} View Presentation {/show} 09:32 AM - 09:52 AM  Debate: EndoAVF is Done vs Surgical Access Deserts What is the role for Endo-AVFs. Learning Objectives Appreciate surigcal success. Appreciate EndoAVF success. Moderator: Dirk Hentschel, MD Panelists: Robert Shahverdyan, MD, PhD; Ahmed Abdel Aal, MD, PhD; Monnie Wasse, MD; Mohamad Hussain, MD, PhD; Surendra Shenoy, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 09:53 AM - 10:23 AM Break AV GRAFTS 10:24 AM - 10:34 AM AV Graft Materials and Configurations Speaker: Jeffrey Lawson, MD, PhD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 10:35 AM - 10:45 AM HeRO Graft - Pros and Cons Speaker: Stephen Hohmann, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} MANAGEMENT OF ACCESS COMPLICATIONS 10:46 AM - 10:56 AM  Management of HAIDI: Which Therapy in Which Stage? Pathophysiology of HAIDI, staging of HAIDI and management of HAIDI based on both stage and pathophysiology. Learning Objectives Understand the pathophysiology and staging. Tailoring of the management options on a case by case basis. Speaker: Yael Vin, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 10:57 AM - 11:07 AM  Preventing HAIDI (Hemodialysis Access Induced Distal Ischemia) How to prevent the devastating outcome of HAIDI (Hemodialysis Access Induced Distal Ischemia) Speaker: Robert Shahverdyan, MD, PhD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 11:08 AM - 11:14 AM Q&A Panel Discussion Panelists: Stephen Hohmann, MD; Jeffrey Lawson, MD, PhD; Robert Shahverdyan, MD, PhD; Yael Vin, MD {show usergroup="OnDemand"} View Presentation {/show} 11:15 AM - 11:35 AM Break 11:36 AM - 11:46 AM High Flow Access Management: Surgical Speaker: John Ross, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 11:47 AM - 11:57 AM  Surgical and Endovascular Management of Aneurysms in AVF's Learn when and how to manage true aneurysms of primary AVFs. Demonstrate some of the surgical techniques in repairing aneurysms of arteriovenous fistulas. Learning Objectives Identify the physical exam findings and access characteristics that lead to the decision to repair an aneurysm. Learn surgical techniques to repair aneurysm of primary arteriovenous fistulas. Speaker: John Lucas, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 11:58 AM - 12:03 PM Surgical and Endovascular Management of Pseudoaneurysms in AV Grafts Speaker: Tristen Chun, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 12:04 PM - 12:09 PM Q&A Panel Discussion Panelists: Tristen Chun, MD; John Lucas, MD; John Ross, MD {show usergroup="OnDemand"} View Presentation {/show} 12:10 PM - 12:40 PM The Henry Keynote Lecture — Vascular Access: The Story of a Specialty (from a Specialist) Speaker: Surendra Shenoy, MD, PhD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 12:40 PM - 01:40 PM  Lunch Symposium - Unwrapping WRAPSODY: Data, Durability, Decisions. This satellite lunch symposium will review recent clinical and real‑world evidence on the WRAPSODY® Cell‑Impermeable Endoprosthesis, with a focus on data published and presented over the past 12–24 months. Expert faculty will translate durability findings, core lab insights, and case experience into practical considerations for contemporary hemodialysis access management. Speakers: Dheeraj Rajan, MD, FRCPC, FSIR, FACR; Ari Kramer, MD Sponsored by: Merit Medical Systems, Inc AV ACCESS MAINTENANCE 01:40 PM - 01:50 PM Access Surveillance - Optimal Methods Speaker: Andrea Lubitz, MD, MPH {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 01:51 PM - 02:01 PM Biology of Intimal Hyperplasia and Strategies for Prevention Speaker: Sanjay Misra, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 02:02 PM - 02:12 PM Covered Stents at the Venous Anastomosis: First Line or Last Line? Speaker: Charles Kim, MD 02:13 PM - 02:23 PM  Drug-Coated Balloons - Most Recent Data This presentation will update participants on the most recent published data related to drug eluting balloons and their applications in vascular access maintenance. We will cover most recent data from pivotal trials and summarize findings of recent meta-analyses. Learning Objectives At the conclusion of this presentation, participants will be able to apply most recent data about drug eluting balloons to decisions about device selection for interventions in AV access interventions. Speaker: Gordon McLennan, MD, FSIR {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 02:24 PM - 02:34 PM  Central Venous Stenosis - When to Treat and How? Update presentation on the best practices to treat central venous stenosis. Learning Objectives Discuss indications, devices, technical details. Discuss how to avoid complications. Speakers: Marcelo Guimaraes, MD, MBA, CPE, FSIR; Alexander Ushinsky, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 02:35 PM - 02:45 PM  Bare vs Covered Stents for Central Veins: What to Use? A review of when to use bare stents, and when to use covered stents for Thoracic Central Vein Obstruction (TCVO) in dialysis patients. Learning Objectives Recognize the limited use of bare stents in the thoracic central veins. Understand the potential for using covered stents in the thoracic central veins. Speaker: Bart Dolmatch, MD, FSIR {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 02:46 PM - 02:54 PM Q&A Panel Discussion Panelists: Bart Dolmatch, MD, FSIR; Charles Kim, MD; Andrea Lubitz, MD, MPH; Gordon McLennan, MD, FSIR; Sanjay Misra, MD; Alexander Ushinsky, MD {show usergroup="OnDemand"} View Presentation {/show} 02:55 PM - 03:10 PM Debate: Venous Anastomosis Stenosis: POBA, DCB, Stent, Stent Graft, Revise? Moderator: Dheeraj Rajan, MD, FRCPC, FSIR, FACR Panelists: Ari Kramer, MD; Stephen Hohmann, MD; Ahmed Abdel Aal, MD, PhD; Dirk Hentschel, MD; Neghae Mawla, MD, FASDIN {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 03:11 PM - 03:41 PM Break 03:42 PM - 03:50 PM  Declotting AV Grafts: How I Do It (Vascular Surgeon) Declotting of arteriovenous grafts from a surgical perspective. Learning Objectives How to do an open declot of an arteriovenous graft. Understanding what are the limitations and advantages of open declots. Speaker: John Lucas, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 03:51 PM - 03:59 PM Declotting AV Grafts: How I Do It (Interventional Nephrologist) Speaker: Neghae Mawla, MD, FASDIN {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 04:00 PM - 04:08 PM  Declotting AV Grafts: How I Do It (Interventional Radiologist) Technical details on graft declots using IR techniques will be discussed. Learning Objectives To understand the technique used for declotting AVG used for dialysis using interventional radiologic techniques. To understand potential complications using IR techniques in graft declots. Speaker: Charles Ray, MD, PhD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 04:09 PM - 04:15 PM Q&A Panel Discussion Panelists: John Lucas, MD; Neghae Mawla, MD, FASDIN; Charles Ray, MD, PhD {show usergroup="OnDemand"} View Presentation {/show} 04:16 PM - 04:26 PM Stent Venous Anastomosis - Consult with Vascular Surgeon or Just Do It? Speaker: John Aruny, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 04:27 PM - 04:37 PM  Stent vs HeRO for Arm Swelling Due to Central Stenosis I will share data from our institution and others comparing outcomes when arm swelling due to central vein stenosis ipsilateral to an AV access is treated with central vein stenting versus HeRO graft conversion. Learning Objectives Learn the technique for two-stage HeRO graft implantation. Familiarize audience with comparitive patency data between HeRO grafts and central venous stents. Speaker: Brendan Cline {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 04:38 PM - 04:48 PM Impact of Hypotension on AV Access Speaker: Jose Navarrete, MD 04:49 PM - 04:59 PM Q&A Panel Discussion Panelists: John Aruny, MD; Brendan Cline; Jose Navarrete, MD {show usergroup="OnDemand"} View Presentation {/show} INNOVATION/BEST ABSTRACTS SESSION 2 05:00 PM - 05:07 PM Xeltis aXess: Transforming Polymer into Living Tissue Speaker: Jason Wagner {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 05:08 PM - 05:15 PM One-year Reintervention Outcomes Following Use of a Cell-Impermeable Endoprosthesis vs. Angioplasty for De Novo vs Restenotic Lesions Speaker: Dheeraj Rajan, MD, FRCPC, FSIR, FACR {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 05:16 PM - 05:23 PM  Self-repair of Acellular Tissue Engineered Vessels (ATEV™) after Cannulation for Dialysis Access Acellular Tissue Engineered Vessels (ATEVs) demonstrated sustained structural integrity, effective healing after repeated cannulation, and enhanced resistance to infection compared with ePTFE grafts, which exhibited progressive wall deterioration and more severe pathological changes. The predominance of lower grade injury in ATEVs, together with evidence of active cellular repair and bacterial containment, highlights their regenerative capacity and ability to support improved host defenses. These findings support ATEVs as a durable, self-repair and infection-resistant vascular access option for long term hemodialysis. Learning Objectives Participants will be able to evaluate and compare current conduits for vascular access through the scope of wall integrity and active tissue repair after repeated cannulations. Participants will be introduced to and will evaluate the Acellular Tissue Engineered Vessel (ATEV) as a biocompatible conduit with enhanced resistance to infection when compared to synthetic ePTFE. Speakers: Maisha Clancy, MA; Juan Wang, PhD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 05:24 PM - 05:31 PM Early Detection of Hemodialysis Access Stenosis Using Contact-Free Optical Monitoring and Predictive Modeling Speakers: Lalathaksha Kumbar, MD, MBA; Hagay Drori, BSc, ME {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 05:35 PM - 05:50 PM VASA Member Business Meeting 05:45 PM - 07:00 PM Reception FRIDAY, MAY 22, 2026 07:00 AM - 08:00 AM Breakfast PERITONEAL DIALYSIS 08:01 AM - 08:11 AM Patient Considerations for PD: Pros and Cons vs HD Speaker: Stephen Hohmann, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 08:12 AM - 08:20 AM How I Do It: PD Catheter Insertion (Surgery) Speaker: Karen Woo, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 08:21 AM - 08:29 AM How I Do It: PD Catheter Insertion (Interventional Nephrology) Speaker: Mohamed Sheta, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 08:30 AM - 08:38 AM How I Do It: PD Catheter Insertion (Interventional Radiology) Speaker: David Strain, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 08:39 AM - 08:45 AM Q&A Panel Discussion Panelists: Stephen Hohmann, MD; Karen Woo, MD; Mohamed Sheta, MD; David Strain, MD; Charles Kim, MD {show usergroup="OnDemand"} View Presentation {/show} 08:46 AM - 09:06 AM Debate: Fistula First or PD Catheter First? Moderator: Mitch Henry; Panel {show usergroup="OnDemand"} Download Presentation View Presentation {/show} HEMODIALYSIS CVC'S 09:07 AM - 09:17 AM When the IJ's are Gone, Where do we Go? Time for a New Paradigm Speaker: Michael Tal, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 09:18 AM - 09:28 AM When ALL the Veins are Gone: Where to go? Speaker: Charles Kim, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 09:29 AM - 09:39 AM  Catheter Locks, Dressings, and Coatings: What Works? This session provides a high-level review of the current evidence regarding catheter locks, specialized dressings, and antimicrobial coatings in the prevention of CRBSI and catheter dysfunction. We will evaluate which technologies offer a statistically significant benefit in the hemodialysis population versus those that remain primarily theoretical. Attendees will leave with a clear, evidence-based framework for selecting the most effective infection-prevention strategies for their clinical practice. Learning Objectives Evaluate the clinical efficacy of various catheter lock solutions, dressings, and antimicrobial coatings in reducing catheter-related bloodstream infections (CRBSI) and improving patency in hemodialysis patients. Develop an evidence-based approach to selecting specific catheter-related technologies by distinguishing between statistically significant clinical benefits and theoretical manufacturer claims. Speaker: Neal Viradia, MD, MPH {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 09:40 AM - 09:46 AM Q&A Panel Discussion Panelists: Charles Kim, MD; Neal Viradia, MD, MPH; David Strain, MD {show usergroup="OnDemand"} View Presentation {/show} 09:47 AM - 10:17 AM Break MISC AV ACCESS TOPICS 10:18 AM - 10:28 AM Post Transplant Access Management: Keep or Ligate? Speaker: Surendra Shenoy, MD, PhD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 10:29 AM - 10:39 AM  Nerve Blocks for Access Creation and Maintenance This presentation will discuss the benefit of nerve blocks in dialysis creation, the types of blocks used, and block adjuncts for both access creation and maintenance. Learning Objectives Learn the benefit of nerve blocks. Learn techniques for nerve blocks. Speaker: Libby Weaver, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 10:40 AM - 10:50 AM Flow Volume Measurements Speaker: Greg Martens, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 10:51 AM - 11:01 AM Frailty and Multi-Morbidity Speaker: Andrea Lubitz, MD, MPH {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 11:02 AM - 11:12 AM  ESKD Life Plan and Access Plan: Surgery Perspective vs Practice Bldg Discuss the National Kidney Foundation ESKD Life - Plan as it relates to access surgery. Learning Objectives At the conclusion of this session, participants will be able to evaluate the patient’s current medical situation, their current and future life goals, their preferences, social support, functional status, logistic and other practical feasibilities when planning access surgery. Speaker: Brittany Aicher, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 11:13 AM - 11:23 AM  Access for Morbid Obesity Morbid obesity presents unique anatomical, hemodynamic, and technical challenges for hemodialysis vascular access creation and maintenance. This presentation reviews the evidence-based strategies for access planning in this population, including vessel mapping considerations, preferred access configurations, and the role of endovascular alternatives. Special attention will be given to perioperative risk stratification and outcomes data specific to patients with a BMI ≥ 40. Attendees will leave with a practical framework to guide individualized access decisions in morbidly obese patients. Learning Objectives Identify the anatomical and physiological factors unique to morbid obesity that influence vascular access selection and surgical planning for hemodialysis. Apply an evidence-based decision framework to optimize access type, site selection, and perioperative management in morbidly obese hemodialysis patients. Speaker: Carlos Hinojosa, MCs {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 11:24 AM - 11:34 AM Q&A Panel Discussion Panelists: Brittany Aicher, MD; Carlos Hinojosa, MCs; Greg Martens, MD; Andrea Lubitz, MD, MPH; Surendra Shenoy, MD, PhD; Libby Weaver, MD {show usergroup="OnDemand"} View Presentation {/show} DEVICE DEVELOPMENT 11:35 AM - 11:45 AM From Back Table to Bedside: Navigating the Gauntlet from Concept to Commercialization of Dialysis Access Devices Speaker: Robert Lee, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 11:46 AM - 11:56 AM  From Clinical Provider to Industry: Device Idea to Clinical Trials and Beyond I will share my story from clinical practice, identifying a clinical need, device development, regulatory affairs, to clinical trials, and acquisition. At the conclusion of this session, participants will be able to recall general steps to take a device from bench to clinical trials. Speaker: Shawn Gage, PA-C {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 11:57 AM - 12:07 PM How do physicians become innovators? Speaker: Jeffrey Lawson, MD, PhD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 12:08 PM - 12:14 PM Q&A Panel Discussion Panelists: Shawn Gage, PA-C; Jeffrey Lawson, MD, PhD; Robert Lee, MD {show usergroup="OnDemand"} View Presentation {/show} 12:15 PM - 01:15 PM Lunch TOP ABSTRACTS 01:16 PM - 01:23 PM  Comparative Effectiveness of Drug-coated Balloons in Dysfunctional Hemodialysis Circuits in Medicare Beneficiaries This comparative effectiveness study utilizes Medicare data to report on real world outcomes of drug-coated vs. uncoated balloon angioplasty for arteriovenous fistulas. Learning Objectives Describe real-world clinical effectiveness outcomes from drug-coated balloon angioplasty. Describe real-world clinical safety outcomes from drug-coated balloon angioplasty. Presenter: Helena Smith, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 01:24 PM - 01:31 PM  Remodeled Cephalic Arch Geometry Promotes Disturbed Flow at Pre-maturation Flow Rates in Hemodialysis Patients In this study, we describe a novel millifluidic model of the cephalic arch that enables us to describe internal hemodynamics at clinically relevant flow rates. We employ these models to 1) calculate venous wall shear stress (WSS), and 2) calculate streamline angle as a metric of flow disturbance. We report that hemodynamic flow disturbance arises in the cephalic arch as a consequence of patient vein geometry and elevated flow rates. Ultimately, we show that remodeled geometry and elevated flow rates create a hemodynamic environment conducive to vascular complications and subsequent access failure. Learning Objectives At the conclusion of this presentation, participants will understand how fistula flow rates promote disturbed flow within the cephalic arch. Presenters: Dylan Cook, Phd(c); Mary Hammes, DO {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 01:32 PM - 01:39 PM  Surgical Management of Cephalic Arch Stenosis via Cephalic Vein Transposition: A Cost-Effective Strategy for Preserving Fistula Patency We present our experience performing surgical treatment-cephalic vein transposition-for management of Cephalic Arch Stenosis on 30 patients on a 6 years period. The analysis and follow up shows consistent clinical outcomes, patency rates and cost-effectivenesss than surpass those reported for endovascular procedures. Learning Objectives At the conclusion of this session participants will be able to evaluate the role of surgical management of Cephalic Arch Stenosis via Cephalic Vein Transposition and compare its consistent results with those reported for endovascular procedures. Presenter: Alexis Garcia-Lopez, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 01:40 PM - 01:47 PM  The Utility of Forearm Loop Arteriovenous Grafts as Part of a Dialysis Access Life Plan This study evaluates the role of forearm loop arteriovenous grafts (flAVG) in hemodialysis access within the context of modern, patient-specific access planning. In a single-institution retrospective analysis, flAVGs demonstrated significantly faster time to cannulation and fewer procedures required for maturation compared to other access types, though they required more interventions to maintain patency and had higher abandonment rates. Despite these trade-offs, overall patency was comparable to other configurations, suggesting that forearm grafts are not inferior as previously reported. These findings support incorporating flAVGs into individualized dialysis “life plans,” particularly for patients needing rapid access while preserving future vascular sites. Presenter: Thomas Coleman, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 01:48 PM - 01:55 PM  Association of Multimorbidity and Frailty with Vascular Access Outcomes Multimorbidity and frailty each play an important role in vascular access outcomes, but their combined effect reveals a more complete picture of patient risk. In this retrospective cohort analysis, we evaluated the association of both these factors, individually and in combination, with hemodialysis vascular access (HDVA) and access abandonment. Patients with both high multimorbidity and frailty experienced the highest rates of access abandonment and worsening outcomes across groups. This highlights the importance of considering the two aspects together to better inform clinical decision-making and risk assessment. Learning Objectives Participants will be able to understand how multimorbidity and frailty independently and jointly influence hemodialysis vascular access abandonment and patient mortality. Participants will be able to recognize the value of considering multimorbidity in combination with frailty to guide shared decision-making and optimize patient outcomes for vascular access creation. Presenter: Sahana Ravishankar, BA {show usergroup="OnDemand"} Download Presentation View Presentation {/show} GLOBAL DIALYSIS ACCESS FORUM 01:56 PM - 02:06 PM Updates in Dialysis Access Care in Japan Speaker: Toshihide Naganuma, MD, PhD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 02:07 PM - 02:17 PM VAS – Dialysis Access in European Nations Speaker: Robert Shahverdyan, MD, PhD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 02:18 PM - 02:28 PM Current Situation of CKD, RRT, and Vascular Access Program in the South East Asia Pacific Region & India Speaker: Sanjiv Jasuja, MD, DNB, MNAMS, FIMSA {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 02:29 PM - 02:39 PM  Necessity: Mother of (Reverse) Innovations: Vascular Access Lessons from the Asia-Pacific Status and trends of renal replacement therapy and vascular access strategies in Asia Pacific region. The region being very heterogeneous, I shall concentrate on India, which has a very active vascular access program with unique problems and solutions which could be in variance with the west. Learning Objectives Peep into the current situation of CKD, RRT and the Vascular Access program in the Asia Pacific region, especially India. There are likely to be some innovations and reverse innovations, which should be worth notable for the American audience. Speakers: Jeyaraj Balasubramaniam, MD, DM, FRCP, FASN; Sanjiv Jasuja, MD, DNB, MNAMS, FIMSA {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 02:40 PM - 02:50 PM VASA – Problems and Initiative in Vascular Access Care in Latin American Countries Speaker: Carlos Hinojosa, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 02:51 PM - 03:01 PM  USA State of Dialysis Access Dialysis access in the US is under government control. However, no regulatory guidelines direct quality expectations for access surgeons. Fiscal incentives and clinical outcomes are not aligned. The variety of anatomic AVF solutions, as well as existing and novel non-autogenous conduit options present cannulators in dialysis units with unsolvable tasks of cognition. Learning Objectives Dialysis access use is part of a complex medical system. Access success hinges on the weakest link. Speaker: Dirk Hentschel, MD {show usergroup="OnDemand"} Download Presentation View Presentation {/show} 03:02 PM - 03:11 PM Discussion 03:12 PM - 03:17 PM Closing Remarks Speaker: Charles Kim, MD", "image": { "@type": "ImageObject", "url": "https://vasamd.org/" }, "publisher": { "@type": "Organization", "name": "Vascular Access Society of the Americas", "logo": { "@type": "ImageObject", "url": "https://vasamd.org//images/gsd.png" } }, "author": { "@type": "Person", "name": "Paul Scarnegie", "url": "https://vasamd.org/events/symposium/symposium-agenda" }, "datePublished": "2025-06-20T21:46:40+00:00", "dateCreated": "2025-06-20T21:46:40+00:00", "dateModified": "2026-06-02T18:21:28+00:00" } ```